Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitors were recommended for the management of diabetes mellitus in 2022 and have shown great potential in the management of MetS (281, 282). The gene discussed is SLC5A2; the disease is metabolic syndrome.